March 20, 2023
A Texas judge removed NantCell Inc. from the unsecured creditors committee in the Chapter 11 case of drugmaker Sorrento Therapeutics on Monday, saying the group's activity is hampered by procedures put in place to address NantCell's conflicts of interest in the case.
March 17, 2023
Shareholders in pharmaceutical research company Sorrento Therapeutics have asked a Texas bankruptcy judge to order the appointment of a committee to represent them in Sorrento's Chapter 11 case and investigate potential claims against the company's management.
February 21, 2023
Bankrupt pharmaceutical research company Sorrento Therapeutics received interim approval Tuesday for a $75 million Chapter 11 loan after a Texas judge overruled objections from a litigation foe of the debtor's that argued the financing wouldn't add value to the estate.
February 13, 2023
California pharmaceutical research firm Sorrento Therapeutics Inc., a developer of cancer, COVID-19 and chronic pain treatments, filed for Chapter 11 protection in a Texas bankruptcy court Monday with about $135 million in debt.